Originally posted here: Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
Originally posted here: Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
More: Bavarian Nordic to hold Capital Markets Days in February 2024
Here is the original post: ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
Go here to read the rest: Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress
Follow this link: Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Visit link: Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
View original post here: MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
See the original post here: Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
Read more here: Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
Read more here: Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences
Recent Comments